News stories about TESARO (NASDAQ:TSRO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. TESARO earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.4856074580613 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

TESARO (NASDAQ:TSRO) traded up $1.61 on Friday, hitting $80.68. 923,002 shares of the company traded hands, compared to its average volume of 806,347. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35. TESARO has a twelve month low of $76.13 and a twelve month high of $192.94. The firm has a market capitalization of $4,299.98, a PE ratio of -9.56 and a beta of 1.52.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm had revenue of $142.77 million for the quarter, compared to analyst estimates of $130.57 million. During the same quarter last year, the firm posted ($1.72) earnings per share. TESARO’s revenue for the quarter was up 740.3% compared to the same quarter last year. research analysts expect that TESARO will post -8.18 earnings per share for the current year.

A number of equities analysts have commented on TSRO shares. Morgan Stanley restated an “overweight” rating and set a $165.00 price objective (down previously from $181.00) on shares of TESARO in a research report on Wednesday, November 8th. Cann reiterated a “buy” rating and issued a $199.00 price target on shares of TESARO in a report on Friday, September 8th. Citigroup reiterated a “buy” rating and issued a $216.00 price target on shares of TESARO in a report on Monday, September 11th. Zacks Investment Research downgraded shares of TESARO from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $158.00 price target on shares of TESARO in a report on Thursday, October 26th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $156.01.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares in the company, valued at $690,529.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 40.50% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://theolympiareport.com/2017/12/23/tesaro-tsro-getting-somewhat-favorable-news-coverage-analysis-shows.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.